WORLD EXCLUSIVE: United States Abandons Universal Hepatitis B Vaccine at Birth – First Major Vaccine Rollback in 33 Years
WORLD EXCLUSIVE: United States Abandons Universal Hepatitis B Vaccine at Birth – First Major Vaccine Rollback in 33 Years
World Report Press | Atlanta/Washington | December 6, 2025
In a move that reverberates far beyond America’s borders, the U.S. Centers for Disease Control and Prevention (CDC) has officially ended the universal administration of the Hepatitis B vaccine to all newborns — a policy in place since 1991 and previously regarded as a global public-health gold standard.
On December 5, 2025, the Advisory Committee on Immunization Practices (ACIP) voted 8–3 to restrict the birth dose exclusively to infants born to Hepatitis B-positive mothers or mothers of unknown status. For the remaining ~99% of U.S. newborns (including those born to screened, negative mothers), the first dose is now deferred until at least 2 months of age under a new “shared clinical decision-making” framework.
The decision, driven by a committee reconstituted earlier this year by Health and Human Services Secretary Robert F. Kennedy Jr., marks the first time a high-income country has walked back a universal birth-dose Hepatitis B immunization policy.
Revised U.S. Hepatitis B Vaccination Schedule (Pending Final HHS Approval)
| Category | 1991–2025 Policy | New 2025 Policy (effective 2026) |
|---|---|---|
| Birth dose (0–24 hours) | Universal – all newborns | Only if mother HBsAg-positive or unknown |
| Low-risk infants (mother HBsAg-negative) | Mandatory birth dose | Optional; defer to ≥2 months |
| Completion of 3-dose series | By 6–18 months | Unchanged timing after first dose delayed |
| Adults 19–59 | Universal recommendation | Unchanged |
Global Implications
- The United States was one of only a handful of countries (along with Canada and parts of Western Europe) that practiced universal Hepatitis B vaccination at birth.
- The World Health Organization (WHO) continues to recommend the birth dose for ALL infants worldwide within 24 hours, a position reaffirmed in 2024.
- Public health model: The dramatic 99% drop in U.S. childhood Hepatitis B infections since 1991 has been cited globally as proof of the birth-dose strategy’s success.
Expert Reaction
- WHO Western Pacific Regional Office (Manila): “Deeply concerned” – the Western Pacific had used the U.S. model to drive down regional prevalence.
- European Centre for Disease Prevention and Control (ECDC): Monitoring closely; no plans to alter European schedules.
- Infectious Diseases Society of America: “A preventable step backward that risks reversing decades of progress.”
Political Context
Secretary Robert F. Kennedy Jr., appointed in 2025, dismissed the prior 17-member ACIP panel and installed new members, several of whom have publicly questioned long-established vaccine safety data. The December 5 meeting featured extended discussion of aluminum adjuvants and theoretical neonatal immune risks — topics repeatedly addressed and dismissed by prior global reviews.
Final sign-off is expected from acting CDC Director Dr. Jim O’Neill or Secretary Kennedy before January 1, 2026.
World Report will continue monitoring how this unprecedented U.S. policy reversal influences immunization strategies in both developed and developing nations.
Keywords: USA Hepatitis B vaccine rollback, CDC ACIP 2025, RFK Jr. vaccine policy, global Hepatitis B birth dose, WHO Hepatitis B recommendation, U.S. newborn vaccination change
